HIMS241206C22000
- 10.15
- +0.65+6.84%
Hims & Hers Health Newsroom
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $38
Hims & Hers Health Analyst Ratings
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $24
Hold Rating on Hims & Hers Health Amidst Regulatory Uncertainty and Market Risks
Hims & Hers Health Analyst Ratings
TD Cowen Reiterates Buy on Hims & Hers Health, Maintains $28 Price Target
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)
BofA Securities Downgrades Hims & Hers Health(HIMS.US) to Sell Rating, Cuts Target Price to $18
Hims & Hers Health Analyst Ratings
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $28
Hims & Hers Health Analyst Ratings
Hims & Hers Health Is Maintained at Hold by Deutsche Bank
Deutsche Bank Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $27
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $24 to $32
Hims & Hers Health: Balancing Strong Performance With Regulatory Uncertainty – Hold Rating Maintained
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)